Holen Sie sich die Stockscreener-App
2.325
6.60%
-0.175
Schlusskurs vom Vortag:
$2.50
Offen:
$2.48
24-Stunden-Volumen:
557.27K
Relative Volume:
0.31
Marktkapitalisierung:
$203.22M
Einnahmen:
$2.24M
Nettoeinkommen (Verlust:
$-136.67M
KGV:
-1.0153
EPS:
-2.29
Netto-Cashflow:
$-102.08M
1W Leistung:
-8.79%
1M Leistung:
+33.43%
6M Leistung:
+366.25%
1J Leistung:
+318.08%
1-Tages-Spanne:
$2.30
$2.58
1-Wochen-Bereich:
$2.30
$3.04
52-Wochen-Spanne:
$0.3418
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Firmenname
Century Therapeutics Inc
Sektor
Branche
Telefon
215-981-4000
Adresse
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.325 | 218.51M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | TD Cowen | Buy |
| 2024-08-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-05-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-12 | Eingeleitet | William Blair | Mkt Perform |
| 2021-07-13 | Eingeleitet | BofA Securities | Buy |
| 2021-07-13 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-13 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives - simplywall.st
Century Therapeutics Reports 2025 Results and Pipeline Progress - TipRanks
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates - Investing News Network
CENTURY THERAPEUTICS ($IPSC) Releases Q4 2025 Earnings - Quiver Quantitative
Century Therapeutics 10-K Summary — Revenue: $— | EPS: $— - TradingView
Bearish Setup: Is Century Therapeutics Inc undervalued by DCF analysis2026 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) to Release Quarterly Earnings on Wednesday - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Raised to "Hold" at Wall Street Zen - MarketBeat
IPSC Financials: Income Statement, Balance Sheet & Cash Flow | Century Therapeutics, Inc. - Stock Titan
Should I buy Century Therapeutics Inc stock nowJuly 2025 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 39.8% in February - MarketBeat
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Closing: How does Century Therapeutics Inc perform in inflationary periodsDollar Strength & Entry Point Confirmation Signals - baoquankhu1.vn
Century Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Century Therapeutics (NASDAQ:IPSC) Coverage Initiated by Analysts at TD Cowen - Defense World
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC) - The Globe and Mail
Movement Recap: Is Century Therapeutics Inc forming a bullish divergenceQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Century Therapeutics to Participate in Upcoming Investor Conferences in March - Investing News Network
Century Therapeutics (NASDAQ:IPSC) Now Covered by Analysts at TD Cowen - MarketBeat
TD Cowen Initiates Century Therapeutics at Buy - marketscreener.com
TD Cowen initiates Century Therapeutics stock rating at Buy - Investing.com Australia
Stem cell therapy biotech Century Therapeutics heads to March investor events - Stock Titan
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) - Defense World
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
What are the future prospects of Century Therapeutics Inc.2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Point72 discloses 6.8% Century Therapeutics (IPSC) stake in 13G/A - Stock Titan
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Is Century Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Big Picture & Short-Term High Return Strategies - mfd.ru
Day Trade: Will Century Therapeutics Inc benefit from seasonality2025 Volume Leaders & High Accuracy Investment Signals - baoquankhu1.vn
Is Century Therapeutics Inc. forming a bullish divergence2025 Performance Recap & Low Volatility Stock Suggestions - mfd.ru
Clear Street reiterates Buy rating on Century Therapeutics stock at $6.60 - Investing.com Canada
Will Century Therapeutics Inc. stock benefit from automationGDP Growth & AI Enhanced Trade Execution Alerts - mfd.ru
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Expands By 320.2% - MarketBeat
Bull Run: Will Century Therapeutics Inc stock go up in YEARShort Setup & Target Return Focused Stock Picks - baoquankhu1.vn
Is Century Therapeutics Inc. stock attractive for ETFs2025 Support & Resistance & Community Verified Trade Signals - mfd.ru
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race - Seeking Alpha
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $3.80 Average PT from Brokerages - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Century Therapeutics (IPSC) Price Target Increased by 10.75% to 4.20 - Nasdaq
Valuation Update: Is Oramed Pharmaceuticals Inc stock overvalued or fairly pricedMarket Growth Review & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Is Century Therapeutics Inc stock undervalued right nowSell Signal & Technical Confirmation Alerts - baoquankhu1.vn
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission - Finviz
Risk Analysis: Will Century Therapeutics Inc benefit from current market trendsDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
Piper Sandler highlights Century Therapeutics (IPSC) cash runway through 2029, upcoming IND submission - MSN
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Grows By 148.0% - MarketBeat
Why retail investors favor Century Therapeutics Inc. stockWeekly Trading Summary & High Accuracy Swing Entry Alerts - mfd.ru
Volume Report: Whats the RSI of Century Therapeutics Inc stock2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Finanzdaten der Century Therapeutics Inc-Aktie (IPSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):